What structural inefficiencies limit value extraction in today’s bioeconomy systems globally? For decades, the bioeconomy has promised transformation. It has spoken the language of sustainability, circularity, and renewable resources, yet in practice it has remained constrained by linear thinking. Biological systems are grown, processed, and commercialized for a narrow set of outputs, while the majority of their molecular and functional complexity is sidelined. Biomass is funneled into a single primary product, even though it contains multiple co-products with distinct market value. The consequence is not merely inefficiency but measurable economic loss. Industries built on biological resources routinely monetize only a fraction of the value embedded in what they cultivate, leaving substantial revenue unrealized. What appears to be resource utilization is, in financial terms, systematic value leakage. How does S-Bridges address value leakage in biological resource processing systems today? S-Bridges was founded to address this utilization gap through a model that integrates biological processing, data infrastructure, and industrial deployment structures. Emerging from Japan with a model that combines deep biological science, digital infrastructure, and industrial pragmatism, the company is building a biomaterial transformation platform designed to recover, quantify, and monetize the value of natural capital that is traditionally left unrealized. Rather than treating biological complexity as waste or an externality, S-Bridges converts it into measurable and investable circular value. Its ambition is to make full-spectrum, use-it-all biomass utilization commercially viable at scale, embedding nature-positive outcomes directly into production decisions and turning value leakage into value creation. “At the center of our ambition is a simple but radical premise. If nature is the most capital-intensive input in the global economy, then 100 percent of biological material must be treated as value, not residue,” says Takashi Nagato, CEO and COO. This premise underpins a proprietary processing system the company calls Cell Breaker^®, designed to make full utilization technically and economically viable.

In the realm of functional skincare, extensive research and industrial practice show that harnessing active ingredients to achieve consistent clinical outcomes is formidable. This is due to difficulty in penetrating the stratum corneum and ensuring stable delivery to targeted skin and hair follicle areas. It is precisely at this bottleneck that cBioMey has developed a ginseng-derived molecular-based active compound delivery system, forming an upgraded platform defined by cBioMey as BISD (Bio-Interactive Structural Delivery). This delivery system transforms the carrier from a mere “transport vehicle” into a functional module with bio-synergistic capabilities. Professor Jiang Zhihong, an internationally renowned natural product pharmacologist and a pioneer in global ginseng research with numerous groundbreaking achievements, is the founder of the technological framework underlying this platform. Unlike traditional formulation systems that regard delivery as a “supportive measure,” cBioMey approaches it from a dermatopharmacological perspective, viewing it as a prerequisite for active ingredients to enter biological pathways. The skin is not a passive surface but a highly dynamic biological system composed of lipid structures, keratinocytes, immune cells, and the follicular microenvironment. Any functional active ingredient can only produce verifiable efficacy after reaching the correct spatial location and participating in the corresponding signaling pathways. cBioMey’s core innovation lies in the development of novel nano-delivery modules, BISD, using rare ginsenosides, replacing the cholesterol component with naturally derived molecular structures. This approach enhances transdermal and transmembrane functions while introducing targeted regulation and synergistic mechanisms. Innovative Structural Delivery of Ginseng Molecules to Replace Cholesterol In classical liposomes and membrane mimetic systems, cholesterol is a critical component for maintaining membrane structural stability and fluidity. However, cBioMey has engineered a natural alternative by systematically screening and reconstructing the molecular structures of ginsenosides, which demonstrates a high degree of compatibility with cholesterol in terms of spatial configuration and membrane phase. This design is not merely a material substitution; rather, it is grounded in two biological foundations: First, the stratum corneum lipid structure and the cell membrane are rich in cholesterol. The introduction of structural similarity enhances the affinity of ginsenoside nanocarriers for the stratum corneum and cell membrane environments, significantly reducing the transmembrane energy barrier..